Loading organizations...
§ Private Profile · San Diego, CA, USA
Truvian Sciences is a technology company.
Truvian Sciences develops an automated benchtop system for comprehensive blood testing. This integrated technology streamlines diagnostics by consolidating multiple laboratory functions into one instrument. The system offers an efficient, accessible alternative to traditional off-site testing, enabling diagnostics closer to patient care.
The company was founded in 2015 by Dena Marrinucci, Ph.D., and others with significant experience across healthcare, diagnostics, and consumer technology. Dr. Marrinucci, a life science executive, previously co-founded Epic Sciences, a liquid biopsy company. Her insight focused on advancing health by introducing innovative diagnostic technologies, inspiring Truvian's integrated platform.
Truvian's product is intended for diverse healthcare settings, enhancing diagnostic capabilities directly at the point of care. The company's vision is to reshape the blood testing industry, making accurate and timely diagnostic information widely available. Truvian strives to improve convenience and accessibility in health management, fostering better patient outcomes.
Truvian Sciences has raised $211.1M across 3 funding rounds.
Truvian Sciences has raised $211.1M in total across 3 funding rounds.
Truvian Sciences has raised $211.1M across 3 funding rounds. Most recently, it raised $74.0M Other Equity in July 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 17, 2024 | $74M Venture Round | Wittington Ventures | — | Announced |
| Feb 1, 2021 | $110M Series C | Wittington Ventures | 7wire Ventures | Announced |
| Nov 25, 2019 | $27.1M Series B | GreatPoint Ventures | — | Announced |
Truvian Sciences has raised $211.1M in total across 3 funding rounds.
Truvian Sciences's investors include Wittington Ventures, 7wire Ventures, GreatPoint Ventures.
Truvian Sciences, now operating as Truvian Health, is a San Diego-based healthcare technology company founded in 2015 that develops an automated benchtop blood testing analyzer called TruVerus. This platform integrates clinical chemistry, immunoassay, and hematology testing in a single run using proprietary disposable discs and support packs with all necessary reagents, delivering lab-accurate results instantly via a secure mobile platform to make routine blood testing convenient, affordable, and actionable for consumers and practitioners.[1][2][3][5] It targets primary care settings, clinics, and point-of-care environments, solving the problem of slow, off-site lab testing by enabling on-site, comprehensive panels like the TruWellness Panel (covering common tests such as lipid panel, comprehensive metabolic panel, and complete blood count), with staged FDA clearances in pursuit.[3][5] The company has raised $207.1 million across four funding rounds, including a recent $74 million, reflecting strong growth momentum amid diagnostics innovation.[3]
Truvian was founded in late 2015 by experts in healthcare, diagnostics, and consumer technology, including co-founder and COO Dena Marrinucci, who previously co-founded Epic Sciences in 2008 as its Chief Scientific Officer, leading liquid biopsy development, diagnostic partnerships, assay work, and CLIA lab establishment for prostate cancer products.[1][2] Key leadership includes CEO and President Jeff Hawkins and board members like Kim P. Kamdar (co-founder and board member), Jay Srinivasan (CEO/board), Tina Nova (recent board appointee with diagnostics/biotech executive experience), and others such as Megh Gupta, Emily Brown, and Ashok Krishnamurthi.[1][3][4] The idea emerged from founders' domain expertise to disrupt blood testing's inefficiencies; early traction built through team expansion with top scientists, engineers, and leaders, plus significant funding and pursuits like FDA clearances, positioning it for commercialization.[1][2][3][5]
Truvian rides the point-of-care diagnostics trend, accelerated by pandemics highlighting delays in traditional lab testing, toward patient-centric healthcare with on-demand, decentralized results.[1][5] Timing aligns with rising demand for affordable routine screening amid chronic disease prevalence (e.g., diabetes, heart conditions via TruWellness panels), fueled by AI/integration advances and consumer tech expectations.[5] Market forces like regulatory support for FDA-cleared benchtop systems and biomanufacturing scalability favor it, similar to peers in precision diagnostics (e.g., Color Genomics, Virta Health).[4] Truvian influences the ecosystem by elevating standards for integrated, on-site testing, potentially reducing healthcare costs and improving access in primary care globally.[1][3]
Truvian is poised for commercialization as it advances staged FDA clearances for its TruVerus platform, expanding the test menu to capture routine blood testing's massive market.[3][5] Key trends like AI-driven diagnostics, telehealth integration, and value-based care will propel growth, with its $207M funding enabling scale amid peers like insitro and Resilience.[3][4] Influence may evolve from innovator to market leader if it achieves full clearances and partnerships, transforming blood testing from a bottleneck to an enabler—disrupting an industry long due for on-site revolution, much like its founders did with liquid biopsies.[1][5]